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Abstract
Introduction: Gastrointestinal relapse in patients with multiple myeloma is very rare and, when reported, always
associated with a poor prognosis.
Case presentation: We describe the case of a 71-year-old Caucasian man who presented with life-threatening
hematemesis and melena due to a digestive relapse of his multiple myeloma. Despite the active hemorrhage, we
initiated a third-line treatment with lenalidomide. The response was spectacular and long-lasting.
Conclusions: Clinicians must consider digestive tract involvement in myeloma patients presenting with a
gastrointestinal hemorrhage. Furthermore, myeloma patients do benefit from novel oral drugs, even when they are
critically ill.
Introduction
The involvement of the gastrointestinal tract years after
an initial diagnosis of multiple myeloma (MM) is excep-
tional and, when reported, always associated with a poor
prognosis [1-4]. We report the case of a 71-year-old
man with MM who had been heavily pre-treated and
who presented with hematemesis and melena due to a
gastrointestinal relapse of his disease. The bleeding
lasted for over two weeks and soon became life-threa-
tening. Despite the active hemorrage, we initiated a
third-line treatment with lenalidomide. The response
was spectacular.
Case presentation
We report the case of a 71-year-old Caucasian diabetic
man with severe diabetic neuropathy who was diagnosed
with stage IIIA IgG l MM in 2004. He was initially trea-
ted with three cycles of vincristine, doxorubicin and
dexamethasone, followed by high-dose melphalan and
autologous stem-cell transplantation, which resulted in a
partial response. His monoclonal IgG had dropped from
65 g/L before treatment to 11 g/L after transplantation.
In 2007, a second-line chemotherapy treatment
(melphalan and prednisone, six cycles) for a relapse
characterized by diffuse spinal involvement and an
increase in monoclonal IgG (22 g/L) stabilized the
disease. His neuropathy had precluded treatment with
thalidomide or bortezomib. Eight months after the sec-
ond-line chemotherapy, an irradiation to the T10-L1
vertebrae (30 Gy) was undertaken for symptomatic,
localized bone involvement. Ten months later, an
increase in his level of IgG (34 g/L), combined with
widespread bone pain and a worsening of his general
condition, led to the introduction of high-dose steroids.
After a week of steroid treatment, he was admitted to
our hospital for the first time with chest pain and dys-
pnea. He was febrile (38.4°C) and his inflammatory para-
meters were increased (C-reactive protein 91 mg/L).
A urinary test for the Legionella pneumophila antigen
was positive and a computed tomography (CT) scan
showed trilobar consolidation and a bilateral pleural
effusion. A heterogeneous solid mass extending from
the retroperitoneal to the peritoneal spaces (Figure 1A,
B) provided evidence for the progression of the MM. At
the time, priority was given to the treatment of the pul-
monary infection and he recovered after three weeks of
oral levofloxacin.
S h o r t l ya f t e rt h ea n t i b i o t i ct h e r a p yw a sd i s c o n t i n u e d ,
he presented with sudden hematemesis and melena,
requiring fifteen 500 ml units of packed red cells, in
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and coagulation parameters were normal. A bleeding,
ulcerated jejunal mass was revealed by an upper gastro-
intestinal endoscopy (Figure 2) and biopsies showed an
infiltration of the intestinal mucosa by neoplastic plasma
cells producing monoclonal l light chains (Figure 3A,B).
Despite the active bleeding, a third-line therapy with
lenalidomide (25 mg daily) and dexamethasone (40 mg
once-weekly) was initiated; the lenalidomide was given
in three-week cycles followed by a one-week break [5,6].
An excellent response was achieved after the first cycle:
his paraprotein levels dropped to 10 g/L and there was
no recurrence of the hematemesis or melena. His gen-
eral condition improved rapidly and he was discharged
after the second cycle had commenced. A repeat CT
four months later showed a dramatic shrinkage of the
retroperitoneal mass (Figure 1C,D). This response lasted
for a total of 10 months and resulted in an excellent
Figure 1 CT of the abdomen before (A, B) and after (C, D) four months of treatment with lenalidomide.
Figure 2 Jejunal mass as seen on the upper gastrointestinal
endoscopy.
Figure 3 Jejunal mucosa infiltrated by multiple myeloma.A :
magnification ×200, hematoxylin and eosin. B: magnification ×400,
l chains.
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He declined further treatment at retroperitoneal pro-
gression and died a few weeks later.
Discussion
Gastrointestinal involvement in MM is very rare. It most
often occurs in the context of an isolated, primary, extra-
medullary plasmacytoma [7]. Patients with newly-
diagnosed MM rarely present with symptoms related to
gastrointestinal involvement [8]. A gastrointestinal
relapse in patients with long-term MM, such as that
observed in the case of our patient, is exceptional.
Amongst a total of 553 patients with MM included in
two large European studies, 87 experienced an extrame-
dullary relapse but none of these involved the gastroin-
testinal tract [1,2]. Only one out of six extramedullary
relapses reported by a North American Institution
involved the gastrointestinal tract [3]. All of these cases
had a poor prognosis, with a maximal survival rate of 106
days from diagnosis. Finally, Dawson et al. reported the
case of a 60-year-old patient with MM with hematemesis,
melena and gastroduodenal mucosal lesions [4]. The
patient died two weeks after presentation. The gastroin-
testinal lesions were not biopsied, but their myelomatous
nature was likely, as a biopsy of a right breast mass pro-
vided pathological evidence of an extramedullary relapse.
Conclusion
Our case report is well documented and highly informa-
tive. It reminds us that, in addition to much more com-
mon causes (for example, ulcers), clinicians must
consider digestive tract involvement in patients with
MM presenting with a gastrointestinal hemorrhage. It
also shows that patients with MM who have been heav-
ily pre-treated can benefit from novel drugs, even when
they are critically ill. We suggest that the major clinical
improvement has to be linked to lenalidomide, since
high-dose steroids had been ineffective in this case. Our
patient’s recovery and the drop in his monoclonal IgG
were very rapid. This effect of lenalidomide has already
been observed in other life-threatening situations asso-
ciated with MM, such as severe renal impairment or
high-output heart failure secondary to intramedullary
arteriovenous fistulas [9,10]. Finally, it should be empha-
sized that a response to this oral drug was obtained
despite active bleeding in the upper digestive tract.
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